Literature DB >> 10163425

Clinical management of patients with insomnia. The role of zopiclone.

G Hajak1, A Rodenbeck.   

Abstract

Insomnia, especially when chronic, is associated with disturbances in daytime well-being and performance, resulting in a poor quality of life for those affected. Zopiclone has been proven as a drug that favourably balances sleep induction and maintenance as well as an improvement in daytime well-being (efficacy) with a low potential for adverse effects (safety) in the symptomatic treatment of insomnia. Management of chronic insomnia with zopiclone needs a multidimensional approach involving the proper diagnosis of possible underlying causes, and combined use of causal treatment, general sleep hygiene measures, basic elements of psychological treatment and adjunctive medication. It is recommended that therapy with the nonbenzodiazepine hypnotic zopiclone should conform to the guidelines for the use of hypnotics, which are valid for all benzodiazepine receptor agonists.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 10163425     DOI: 10.2165/00019053-199600101-00006

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  56 in total

Review 1.  Drug therapy: The diagnosis and management of insomnia.

Authors:  J C Gillin; W F Byerley
Journal:  N Engl J Med       Date:  1990-01-25       Impact factor: 91.245

2.  Effect of benzodiazepine hypnotics on all-night sleep EEG spectra.

Authors:  A A Borbély; P Mattmann; M Loepfe; I Strauch; D Lehmann
Journal:  Hum Neurobiol       Date:  1985

Review 3.  Zopiclone, the third generation hypnotic: a clinical overview.

Authors:  B Musch; F Maillard
Journal:  Int Clin Psychopharmacol       Date:  1990-04       Impact factor: 1.659

4.  Sleep habits and sleep disturbances among the elderly--an epidemiological survey.

Authors:  T Gíslason; H Reynisdóttir; H Kristbjarnarson; B Benediktsdóttir
Journal:  J Intern Med       Date:  1993-07       Impact factor: 8.989

5.  Effects of zopiclone on quality of life in insomnia.

Authors:  I Hindmarch
Journal:  Eur Psychiatry       Date:  1995       Impact factor: 5.361

6.  Daytime sleepiness: a risk factor in community life.

Authors:  K Martikainen; J Hasan; H Urponen; I Vuori; M Partinen
Journal:  Acta Neurol Scand       Date:  1992-10       Impact factor: 3.209

7.  Treatment of primary insomnia with trimipramine: an alternative to benzodiazepine hypnotics?

Authors:  F Hohagen; R F Montero; E Weiss; S Lis; E Schönbrunn; H Dressing; D Riemann; M Berger
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1994       Impact factor: 5.270

8.  Histaminergic systems and sleep. Studies in man with H1 and H2 antagonists.

Authors:  A N Nicholson; P A Pascoe; B M Stone
Journal:  Neuropharmacology       Date:  1985-03       Impact factor: 5.250

9.  Diphenhydramine in insomniac family practice patients: a double-blind study.

Authors:  K Rickels; R J Morris; H Newman; H Rosenfeld; H Schiller; R Weinstock
Journal:  J Clin Pharmacol       Date:  1983 May-Jun       Impact factor: 3.126

Review 10.  Rebound insomnia: its determinants and significance.

Authors:  T Roehrs; G Vogel; T Roth
Journal:  Am J Med       Date:  1990-03-02       Impact factor: 4.965

View more
  4 in total

Review 1.  Zaleplon: a review of its use in the treatment of insomnia.

Authors:  M Dooley; G L Plosker
Journal:  Drugs       Date:  2000-08       Impact factor: 9.546

Review 2.  Zopiclone. An update of its pharmacology, clinical efficacy and tolerability in the treatment of insomnia.

Authors:  S Noble; H D Langtry; H M Lamb
Journal:  Drugs       Date:  1998-02       Impact factor: 9.546

3.  Zopiclone: is it a pharmacologic agent for abuse?

Authors:  Nevio Cimolai
Journal:  Can Fam Physician       Date:  2007-12       Impact factor: 3.275

Review 4.  A comparative assessment of the risks and benefits of zopiclone: a review of 15 years' clinical experience.

Authors:  G Hajak
Journal:  Drug Saf       Date:  1999-12       Impact factor: 5.228

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.